Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan

Oncology

Volumn 78, Issue SUPPL. 1, 2010, Pages 154-166

  Kudo, Masatoshi ^a   Ueshima, Kazuomi ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Complete remission; Hepatocellular carcinoma; Liver cancer treatment algorithm; Molecular targeted therapy; Sorafenib; Tyrosine kinase inhibitor

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ALPHA FETOPROTEIN; BELINOSTAT; BEVACIZUMAB; BRIVANIB; CEDIRANIB; CETUXIMAB; DECARBOXYPROTHROMBIN; ERLOTINIB; EVEROLIMUS; FLT3 LIGAND; GEFITINIB; LAPATINIB; LINIFANIB; NIK 333; PI 88; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RETINOID; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TAC 101; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN;

ADRENAL METASTASIS; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; CANCER INVASION; CANCER REGRESSION; CELL PROLIFERATION; CHEMOEMBOLIZATION; CONSENSUS; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GENE MUTATION; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; LUNG METASTASIS; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PORTAL VEIN; PRIORITY JOURNAL; REVIEW;

ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954509572     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315245     Document Type: Review

References (32)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
3. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, et al: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
5. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140.
6. Rini BI: Sorafenib. Expert Opin Pharmacother 2006; 7: 453-461.
7. Wu H, Huang C, Chang D: Anti-angiogenic therapeutic drugs for treatment of human cancer. J Cancer Mol 2008; 4: 37-45.
8. Kano MR, Komuta Y, Iwata C, Oka M, Shirai YT, Morishita Y, Ouchi Y, et al: Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci 2009; 100: 173-180.
9. Tanaka S, Arii S: Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 2009; 100: 1-8.
10. Llovet JM, Bruix J: Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327.
11. Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, et al: Management of Hepatocellular Carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology 2009. Hepatol Res 2010, in press.
12. Japan Association of Molecular Targeted Therapy: 1st Meeting Abstract Book. Osaka, Japan Association of Molecular Targeted Therapy, 2010.
13. Wang SX, Byrnes A, Verma S, Pancoast JR, Rixe O: Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report. Target Oncol 2010, Epub ahead of print.
14. So BJ, Bekaii-Saab T, Bloomston MA, Patel T: Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol 2008; 1: 18.
15. Spangenberg HC, Thimme R, Blum H: Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:423-432.
16. Faivre S, Raymond E, Douillard J, et al: Assessment of safety and drug induced tumor necrosis with sunitinib in patients with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2007; 25: 149s.
17. Zhu A, Sahani D, Duda DG, di Tomaso E, et al: Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009; 27: 3027-3035.
18. Abou-Alfa GK, Schwartz L, Ricci S, et al: Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-4300.
19. Raoul JL, Flinn RS, Kang YK, et al: An openlabel phase II study of first-and second-line treatment with brivanib in patients with hepatocellular carcinoma. J Clin Oncol 2009; 27:15S; Abstr 4577.
20. Toh H, Chen PJ, Carr BI, et al: A phase II study of ABT-869 in hepatocellular carcinoma: interim analysis. J Clin Oncol 2009;27: 15S; Abstr 4581.
21. Siegel AB, Cohen EI, Ocean A, et al: Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26: 2992-2998.
22. Philip PA, Mahoney MR, Allmer C, et al: Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-6663.
23. Thomas MB, Chadhal R, Glover K, et al: Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-1066.
24. O'Dwyer PJ, Giantonio BJ, Levy DE, et al: Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203. J Clin Oncol 2006;24:18S; Abstr 4143.
25. Ramanathan RK, Belani CP, Singh DA, et al: A phase II study of Lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009; 64:777-783.
26. Bekaii-Saab T, Markowitz J, Prescott N, et al: A multiinstitutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res 2009;15:5895-5901.
27. Zhu AX, Stuart K, Blaszkowsky LS, et al: Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007;110:581-589.
28. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, et al: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334: 1561-1567. (Pubitemid 26177483)
29. Muto Y, Moriwaki H, Saito A: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999; 340: 1046-1047.
30. Sherman M, Mazzaferro V, Amadori D, et al: Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: a subanalysis from the SHARP trial. J Clin Oncol 2008;26(suppl); Abstr 4584.
31. Kudo M, Okanoue T: Management of hepatocellular carcinoma in Japan: consensusbased clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72(suppl):2-15.
32. Kudo M: Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology 2008; 75 (suppl):1-12.